1 임동준, "갑상선암에서 표적치료항암제의 피부 관련 부작용" 대한갑상선학회 11 (11): 82-87, 2018
2 Resteghini C, "Management of tyrosine kinase inhibitors(TKI)side effects in differentiated and medullary thyroid cancer patients" 31 : 349-361, 2017
3 Capozzi M, "Lenvatinib, a molecule with versatile application : from preclinical evidence to future development in anti-cancer treatment" 11 : 3847-3860, 2019
4 Schlumberger M, "Lenvatinib versus placebo in radioiodinerefractory thyroid cancer" 372 : 621-630, 2015
5 Erber R, "Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms" 18 : 338-340, 2004